oa Tirzepatide: A Turning Point in Pharmacotherapy for Obesity and Type 2 Diabetes in Adults

References

1. DharmarajanT.S. DavuluriS. Prescribing medications for older adults: Dealing with obesity, misuse, polypharmacy and adverse drug events!Obesity and disease in an interconnected world: A systems approach to turn huge challenges into amazing opportunities.Bentham Science Publishers201528130510.2174/9781681080369115010020
   [Google Scholar]
2. AasethJ. EllefsenS. AlehagenU. SundførT.M. AlexanderJ. Diets and drugs for weight loss and health in obesity – An update.Biomed. Pharmacother.202114011178910.1016/j.biopha.2021.11178934082399
   [Google Scholar]
3. LiuQ.K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.Front. Endocrinol.202415143129210.3389/fendo.2024.143129239114288
   [Google Scholar]
4. FismanE.Z. TenenbaumA. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect.Cardiovasc. Diabetol.202120122510.1186/s12933‑021‑01412‑534819089
   [Google Scholar]
5. BagsværdD. Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes.2022Available from: https://www.globenewswire.com/news-release/2022/08/22/2502111/0/en/Novo-Nordisk-successfully-completes-phase-2-trial-with-CagriSema-in-people-with-type-2-diabetes.html
6. BenichouO. CoskunT. GonciarzM.D. GarhyanP. AdamsA.C. DuY. DunbarJ.D. MartinJ.A. MatherK.J. PickardR.T. ReynoldsV.L. RobinsD.A. ZvadaS.P. EmmersonP.J. Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.Cell Metab.2023352274286.e1010.1016/j.cmet.2022.12.01136630958
   [Google Scholar]
7. FríasJ.P. An update on tirzepatide for the management of type 2 diabetes: A focus on the phase 3 clinical development program.Expert Rev. Endocrinol. Metab.202318211113010.1080/17446651.2023.218479636908082
   [Google Scholar]
8. FríasJ.P. DaviesM.J. RosenstockJ. Pérez ManghiF.C. Fernández LandóL. BergmanB.K. LiuB. CuiX. BrownK. SURPASS-2 Investigators Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.N. Engl. J. Med.2021385650351510.1056/NEJMoa210751934170647
   [Google Scholar]
9. JastreboffA.M. AronneL.J. AhmadN.N. WhartonS. ConneryL. AlvesB. KiyosueA. ZhangS. LiuB. BunckM.C. StefanskiA. SURMOUNT-1 Investigators Tirzepatide once weekly for the treatment of obesity.N. Engl. J. Med.2022387320521610.1056/NEJMoa220603835658024
   [Google Scholar]
10. HaddadF. DokmakG. BaderM. KaramanR. A comprehensive review on weight loss associated with anti-diabetic medications.Life2023134101210.3390/life1304101237109541
    [Google Scholar]